Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Tae H Han"'
Autor:
Linda G Eissenberg, Julie K Ritchey, Michael P Rettig, Dilan A Patel, Kiran Vij, Feng Gao, Victoria Smith, Tae H Han, John F DiPersio
Publikováno v:
PLoS ONE, Vol 19, Iss 5, p e0300174 (2024)
Off-the-shelf immunotherapeutics that suppress tumor growth and provide durable protection against relapse could enhance cancer treatment. We report preclinical studies on a CD33 x CD3 bivalent bispecific diabody, AMV564, that not only suppresses tum
Externí odkaz:
https://doaj.org/article/8c314f5537e44cf58287f597f11ec364
Autor:
Nancy L. Bartlett, Eric L. Sievers, Tae H. Han, Dana A. Kennedy, Anna R. Franklin, Ranjana H. Advani, Joseph D. Rosenblatt, Andres Forero-Torres, Michelle A. Fanale
PDF file - 45KB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a4b26bfcf437c416d70034b20e086ce
https://doi.org/10.1158/1078-0432.22447601.v1
https://doi.org/10.1158/1078-0432.22447601.v1
Autor:
Nancy L. Bartlett, Eric L. Sievers, Tae H. Han, Dana A. Kennedy, Anna R. Franklin, Ranjana H. Advani, Joseph D. Rosenblatt, Andres Forero-Torres, Michelle A. Fanale
Purpose: The antibody–drug conjugate (ADC) brentuximab vedotin comprises a CD30-directed antibody covalently attached to the potent antimicrotubule agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. This study explored the safety
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50b168f5c74b39535b2a7a2125a3ed84
https://doi.org/10.1158/1078-0432.c.6521135.v1
https://doi.org/10.1158/1078-0432.c.6521135.v1
Autor:
Nancy L. Bartlett, Eric L. Sievers, Tae H. Han, Dana A. Kennedy, Anna R. Franklin, Ranjana H. Advani, Joseph D. Rosenblatt, Andres Forero-Torres, Michelle A. Fanale
PDF file - 67KB, Median duration of overall objective response and complete remission by Kaplan-Meier analysis.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beba621aaa0ccf0e4fb2e00374b0b4f5
https://doi.org/10.1158/1078-0432.22447604
https://doi.org/10.1158/1078-0432.22447604
Autor:
Nancy L. Bartlett, Eric L. Sievers, Tae H. Han, Dana A. Kennedy, Anna R. Franklin, Ranjana H. Advani, Joseph D. Rosenblatt, Andres Forero-Torres, Michelle A. Fanale
PDF file - 73KB, Suppl Table 1. Multiple Dose Pharmacokinetic Parameters for MMAE Suppl Table 2. Best Clinical Response Rate by Diagnosisa (efficacy evaluable population).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e973710e8435baf083980574777d60c6
https://doi.org/10.1158/1078-0432.22447598
https://doi.org/10.1158/1078-0432.22447598
Autor:
Nancy L. Bartlett, Eric L. Sievers, Tae H. Han, Dana A. Kennedy, Anna R. Franklin, Ranjana H. Advani, Joseph D. Rosenblatt, Andres Forero-Torres, Michelle A. Fanale
PDF file - 76KB, Dose proportionality. (A) --- Area under the curve for brentuximab vedotin; (B) --- Area under the curve for free MMAE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31d407c996b7b90e212a488dd2d2adbc
https://doi.org/10.1158/1078-0432.22447607.v1
https://doi.org/10.1158/1078-0432.22447607.v1
Publikováno v:
Cancer Research. 82:1758-1758
PRO1102 is an antibody-drug conjugate (ADC) directed toward HER2, a validated protein target that is overexpressed in multiple cancers, including breast and gastrointestinal cancer. PRO1102 is comprised of 1) trastuzumab, a clinically and commerciall
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aba996ce8e97a265381b5ea3c2bf76b
https://doi.org/10.1158/1538-7445.am2022-1758
https://doi.org/10.1158/1538-7445.am2022-1758
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:347-354
Monomethyl auristatin E (MMAE), the toxin linked to CD30-specific monoclonal antibody of Adcetris® (brentuximab vedotin), is a potent anti-microtubule agent. Brentuximab vedotin has been approved for the treatment of relapsed or refractory Hodgkin l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15e9937d2fb4d9eeef3e52a3cca91adb
https://doi.org/10.1007/s13318-017-0455-5
https://doi.org/10.1007/s13318-017-0455-5
Publikováno v:
The Journal of Clinical Pharmacology. 57:S11-S25
Antibody-drug conjugates (ADCs) represent an innovative therapeutic approach that provides novel treatment options and hope for patients with cancer. By coupling monoclonal antibodies (mAbs) to cytotoxic small-molecule payloads with a plasma-stable l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5219fa54c09d88bebe8bc4c1abbe70e
https://doi.org/10.1002/jcph.981
https://doi.org/10.1002/jcph.981
Autor:
Satwant Lally, Bharathi Vennapusa, Scott J. Dylla, M. Catherine Pietanza, Todd M. Bauer, Sky Watson, Melissa Lynne Johnson, Howard A. Burris, Bonnie S. Glisson, Deepan Mathur, Lauren Averett Byers, Hany Zayed, Charles M. Rudin, David R. Spigel, Francisco Robert, Tae H. Han, Sheila Bheddah, Donald K Strickland, Ramaswamy Govindan, Daniel Morgensztern, Neal Ready, Stanford L. Peng, Noah Theiss
Publikováno v:
The Lancet Oncology. 18:42-51
Summary Background Rovalpituzumab tesirine is a first-in-class antibody-drug conjugate directed against delta-like protein 3 (DLL3), a novel target identified in tumour-initiating cells and expressed in more than 80% of patients with small-cell lung
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a8216db6c1c8093641d3464207a88e
https://doi.org/10.1016/s1470-2045(16)30565-4
https://doi.org/10.1016/s1470-2045(16)30565-4